Kamada Reports Strong Third Quarter and Nine Month 2025 Financial Results with over 30% Year-over-Year Profitability Growth

Year, and Adjusted EBITDA of $11.7 Million, up 34% Year-Over YearNine Month Revenue of $135.8 Million, up 11% Year-over-Year; ...
Le Lézard

Vir Biotechnology Announces AASLD The Liver Meeting® Presentation & New England Journal of Medicine Publication of Phase 2 Data Demonstrating Tobevibart & Elebsiran ...

Vir Biotechnology, Inc. today announced that Week 48 endpoint analysis from the Company's Phase 2 SOLSTICE trial for chronic hepatitis delta (CHD) demonstrated that participants receiving a monthly ...